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SObjective: Invasive lung tumors are associated with intercellular adhesion molecule-1 (ICAM-1) expression.
Secretory phospholipase A2 (sPLA2) enzymes produce inflammatory mediators that stimulate ICAM-1 expres-
sion, and upregulation of PLA2 activity can enhance metastasis. We hypothesize a link between sPLA2 activity,
ICAM-1 expression, and tumor cell invasion. We propose that inhibition of sPLA2 modulates ICAM-1 expres-
sion in cancer cells and attenuates their invasiveness.
Methods: Human lung adenocarcinoma cells (A549) were treated with an ICAM-1 blocking antibody and as-
sayed for invasion. Lung cancer cells (A549 and H358) were then treated with an sPLA2 inhibitor and evaluated
by immunoblotting for ICAM-1 expression. Next cells (A549) treated with sPLA2 inhibitor were assayed for
invasion. Finally, sPLA2 messenger RNA and protein expression were evaluated by quantitative reverse-
transcriptase polymerase chain reaction and immunofluorescence microscopy, respectively. Statistical analysis
was performed by the Student t test or analysis of variance, as appropriate.
Results: Antibody blockade of ICAM-1 decreased lung cancer cell invasion. sPLA2 inhibition significantly re-
duced ICAM-1 expression and invasion. sPLA2 inhibition also significantly decreased sPLA2 mRNA expression
and immunofluorescent staining of sPLA2.
Conclusions: sPLA2 plays a significant role in mediating the inflammatory signals that induce ICAM-1 expres-
sion in lung cancer cells. Inhibition of the enzyme can significantly decrease ICAM-1 expression and subsequent
cancer cell invasion. This lays the groundwork for further investigation into the cellular mechanisms of sPLA2
and its role in lung cancer. (J Thorac Cardiovasc Surg 2012;143:405-11)G
TApproximately 75% of patients with lung cancer have met-
astatic disease at the time of diagnosis, andmortality largely
results from the burden of metastatic spread.1 Improving
therapy for patients with invasive disease could dramati-
cally affect lung cancer mortality and morbidity.
Metastatic cancer cells undergo a structural alteration to
invade neighboring tissue. Invasion can be facilitated by ex-
pression of adhesion molecules such as intercellular adhe-
sion molecule-1 (ICAM-1).2 ICAM-1 is a member of the
immunoglobulin supergene family of adhesion molecules
and its expression is essential for the transendothelial mi-
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The Journal of Thoracic and CaIn malignant disease, ICAM-1 expression has been associ-
ated with more aggressive lesions in melanoma, gastric,
breast, lung, and other epithelial-derived cancers.2,3
Serum ICAM-1 levels are increased in patients with non–
small cell lung cancer,4 and elevated serum levels have
been correlated with advanced cancer stage.5-7
Histologically, levels of ICAM-1 expression in lung cancer
tissue are proportional to tumor stage and associated with
metastatic spread to lymph nodes.7,8 Laboratory models
have demonstrated that ICAM-1 upregulation can promote
cancer cell invasion. Furthermore, decreased tumor cell in-
vasion is associated with decreased levels of ICAM-1
expression.7,9
Secretory phospholipase A2 (sPLA2) enzymes produce
inflammatory mediators that stimulate ICAM-1 expression.
These enzymes catalyze the release of arachidonic acid from
cell membranes leading to the production of eicosanoids
such as prostaglandins, thromboxanes, and leukotri-
enes.10,11 Recently a number of studies have looked
beyond the role of phospholipase enzymes in
inflammation to probe their contribution to the
pathogenesis of cancer.12-17 Stimulation of phospholipase
A2 (PLA2) activity enhances the metastatic potential of
lung cancer cells in vivo.13 Interestingly, PLA2 activity in
tumor-associated macrophages also correlates with a morerdiovascular Surgery c Volume 143, Number 2 405
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FIGURE 1. Intercellular adhesion molecule-1 (ICAM-1) determines inva-
siveness of lung adenocarcinoma cells. Statistically significant reduction in
invasion of A549 cells pretreated with a neutralizing ICAM-1 antibody.
*P ¼ .003 compared with antibody control, n ¼ 9.
Abbreviations and Acronyms
DMSO ¼ dimethyl sulfoxide
ICAM-1 ¼ intercellular adhesion molecule-1
mRNA ¼ messenger RNA
PBS ¼ phosphate-buffered saline
PLA2 ¼ phospholipase A2
sPLA2 ¼ secretory phospholipase A2
TNF-a ¼ tumor necrosis factor-alpha
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Sinvasive phenotype in vivo.12 Regarding sPLA2 specifically,
pharmacologic inhibition of the enzyme in lung cancer cells
increases apoptosis and attenuates proliferation.17 Inhibition
of sPLA2 has also been shown to attenuate total cellular and
soluble ICAM-1 expression in esophageal cancer cells.16
We hypothesize a link between sPLA2 and ICAM-1 in
lung cancer cells. We propose that sPLA2 mediates ICAM-
1 expression in lung cancer cells and that inhibition of
sPLA2 decreases the invasive potential of lung cancer cells.MATERIALS AND METHODS
Cell Culture and Reagents
Two human non–small cell lung cancer cell lines were used. A549 cells
were donated by Dr Banerjee (University of Colorado, Aurora, Colo). NCI-
H358 cells were a gift from Dr O’Neill (Brigham Young University, Provo,
Utah). Cells were maintained at 37C in 5% carbon dioxide in Ham’s F-12
(A549) or RMPI (H358) containing 10% fetal bovine serum. Stock and ex-
perimental solutions of tumor necrosis factor-alpha (TNF-a) (Sigma Al-
drich, St Louis, Mo) were prepared in phosphate-buffered saline (PBS).
The group IIa sPLA2 inhibitor S3319 (Sigma Aldrich) was dissolved in di-
methyl sulfoxide (DMSO). DMSO served as a vehicle control for all exper-
iments with a maximum experimental concentration of 0.08%. DMSOwas
used for the same time points as the inhibitor. Rabbit anti-ICAM-1 (Santa
Cruz Biotechnology, Inc, Santa Cruz, Calif) and anti-glyceraldehyde-3-
phosphate antibodies (Cell Signaling Technology, Inc, Danvers, Mass)
were used forWestern blot. Sheep anti-ICAM-1 and a polyclonal sheep im-
munoglobulin G control (R&D Systems,Minneapolis, Minn) were used for
ICAM-1 blockade experiments.
Matrigel Invasion Assay
A modified Boyden chamber assay was created using Transwell 8-mm
permeable inserts (Corning, Corning, NY) coated with 20-mg/100 mL Ma-
trigel matrix (BD Biosciences, Franklin Lakes, NJ) placed in 24-well cell
culture plates. For the neutralizing antibody experiment, A549 cells were
plated in full media (media with 10% fetal bovine serum) for 24 hours
and then serum-starved (media with 0.5% fetal bovine serum) for 24 hours
before adding TNF-a for 8 hours. Cells were trypsinized, counted, and re-
suspended in serum-starved media containing ICAM-1 neutralizing anti-
body (25 mg/mL) in a rotating incubator for 1 hour at 37C. An aliquot
of cells incubated with sheep immunoglobulin G at the same concentration
served as an antibody control. Then, 53 104 cells were placed on each in-
sert and allowed to migrate for 36 hours using full media with 10% fetal
bovine serum as a chemoattractant in the bottom chamber. Inserts were
fixed and stained with 0.4% crystal violet, 0.2-mol/L citrate for 1 hour,
washed twice with PBS, then once with deionized water. Cells on the upper
side of the insert were removed with a cotton swab. Remaining cells in the
center of the insert were counted using a stereomicroscope (Leica,Wetzlar,406 The Journal of Thoracic and Cardiovascular SurgGermany) and SPOT basic imaging software (SPOT Imaging Solutions,
Sterling Hills, Mich).
For the sPLA2 inhibitor invasion assay, A549 cells were first grown in
25-mL flasks at a concentration of 7 3 106 cells/mL for 24 hours and
then serum-starved for 24 hours. Control cells were incubated with
DMSO in serum-starved media, and then TNF-a was added to the media
for 8 hours. Treatment cellswere incubatedwith 20-mmol/L sPLA2 inhibitor
in serum-starved media for 1 hour, and then 20-ng/mLTNF-awas added to
the treatmentmedia for 8 hours.After cellswere counted and resuspended in
serum-starved media, 53 104 cells were placed on each insert and allowed
to migrate for 36 hours. Cells were stained and counted as described.
Western Blot Analysis
For analysis, 3 3 106 cells were plated in 6-well culture plates in full
media for 24 hours and then serum-starved for 24 hours before treatment.
Cells were incubated with incrementally increasing concentrations of the
sPLA2 inhibitor in serum-starved media for 1 hour; then 20-ng/mL
TNF-a was added to the treatment media for 8 hours. Control cells were
incubated with DMSO in serum-starved media and stimulated with TNF-
a for 8 hours. Cells were lysed with Laemelli buffer and proteins resolved
using sodium dodecyl sulfate–polyacrylamide gel electrophoresis. The
proteins were transferred to nitrocellulose membranes and probed for
ICAM-1 and glyceraldehyde-3-phosphate. Blocking solution contained
0.5% nonfat milk in 13 PBS with 0.1% Tween-20. Antibodies were di-
luted in 5% bovine serum albumin and 13 PBS with 0.1% Tween-20. Af-
ter incubation with horse radish peroxidase–conjugated secondary
antibody, bound antibody was detected using enhanced chemilumines-
cence (Pierce Protein Research Products; Thermo Scientific, Rockford,
Ill). Image J software (National Institutes of Health, Bethseda, Md) was
used for densitometric analysis of the protein band of interest.
Lactic Dehydrogenase Cytotoxicity Assay
Cells, 5000 per well, were plated in a 96-well culture plate and treated as
described for Western blot analysis of ICAM-1 expression. Cell superna-
tants were assayed for lactic dehydrogenase activity per manufacturer in-
structions (Cayman Chemicals, Ann Arbor, Mich).
Immunofluorescence Microscopy
Cells, 5000 per chamber, were cultured onLab-Tek II 8-well glass cham-
ber slides (ThermoScientific, Rochester, NY) in full media for 24 hours and
then serum-starved for 24 hours. Cells were pretreated with incrementallyery c February 2012
FIGURE 2. Decreased total cellular expression of intercellular adhesion molecule-1 (ICAM-1) in lung adenocarcinoma cells treated with secretory phos-
pholipase A2 (sPLA2) inhibitor. RepresentativeWestern blot of A549 cells and H358 cells shows a concentration-dependent decrease in ICAM-1 expression
(A). Densitometric analysis of ICAM-1 protein bands normalized to vehicle control. A statistically significant decrease in ICAM-1 expression was seen in
both cell lines (B). *P<.001 compared with control, n ¼ 4 for each experiment. GAPDH, Glyceraldehyde-3-phosphate.
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Sincreasing concentrations of the sPLA2 inhibitor in serum-starvedmedia for
1 hour and then stimulated with 20-ng/mLTNF-a for 8 hours. Control cells
were incubated with DMSO in serum-starved media and stimulated with
TNF-a for 8 hours. Immunofluorescence microscopy was performed to
evaluate sPLA2 expression in A549 cells as previously described.
15
Reverse-Transcriptase Polymerase Chain Reaction
Cells were grown in 12-well culture plates at a density of 1 3 105
cells per well with full media and then serum-starved media for 24FIGURE 3. Secretory phospholipase A2 (sPLA2) inhibition of lung adenocar
matrix. Representative image of cells that have migrated through the matrix (A
20-mmol/L sPLA2 inhibitor for 8 hours (B). *P ¼ .019 compared with control,
The Journal of Thoracic and Cahours each. Cells were incubated with 20-mmol/L sPLA2 inhibitor for
1 hour before TNF-a was added for 2 hours, 1 hour, and 30 minutes be-
fore messenger RNA collection. Control cells were incubated with
DMSO in serum-starved media and stimulated with 20-ng/mL TNF-a
for the same time points. A549 cells were analyzed for mRNA expres-
sion of sPLA2 using quantitative reverse-transcriptase polymerase
chain reaction as previously described.15 Messenger RNA for sPLA2
was normalized to mRNA for glyceraldehyde-3-phosphate in the
same sample.cinoma cells decreases invasion through a modified basement membrane
). Statistically significant reduction in invasion of A549 cells treated with
n ¼ 17.
rdiovascular Surgery c Volume 143, Number 2 407
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FIGURE 4. Representative immunofluorescent images of group IIa secretory phospholipase A2 (sPLA2) expression in A549 cells. Cell membranes
appear green, nuclei appear blue, and sPLA2 appears red. The negative control was cells in vehicle control media and tumor necrosis factor-alpha
(TNF-a) for 8 hours stained with non–immune matched immunoglobulin G (A). In the subsequent images, cells were stained with group IIa sPLA2
antibody, vehicle control, and TNF-a for 8 hours (B), TNF-a for 8 hours in the presence of 20-mmol/L sPLA2 inhibitor (C), and TNF-a for 8 hours
in the presence of 40-mmol/L sPLA2 inhibitor (D). The decrease in sPLA2 staining was significant at 40-mmol/L sPLA2 inhibitor compared with control
(E). *P ¼ .023.
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SStatistical Analysis
All data distributions were inspected before statistical analysis. The Stu-
dent t test was performed for 2 group comparisons, and an analysis of var-
iance test was performed when comparing 3 or more groups. No multiple
comparisons were conducted. SAS version 9.2 (SAS Institute, Inc, Cary,
NC) was used for all statistical analysis.
RESULTS
ICAM-1 Blockade Decreases Invasion of A549 Cells
Cells treated with a neutralizing ICAM-1 antibody
demonstrated significantly decreased invasion, over
70% compared with an antibody control (Figure 1,
P ¼ .003).408 The Journal of Thoracic and Cardiovascular SurgsPLA2 Inhibition Reduces ICAM-1 Expression and
Attenuates Invasion
Treatment of A549 and H358 cells with a specific group
IIa sPLA2 inhibitor led to a concentration-dependent de-
crease in ICAM-1 expression in both cell lines with
a greater than 80% decrease at the maximum concentra-
tion of 40 mmol/L (Figure 2, A and B, P< .001, at 15,
20, and 40 mmol/L in both cell lines). The concentrations
used did not cause cell lysis as evaluated by a lactic dehy-
drogenase cytotoxicity assay (data not shown). Invasion of
A549 cells through a modified basement membrane
matrix was significantly decreased in the presence ofery c February 2012
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FIGURE 5. Group IIa secretory phospholipase A2 (sPLA2) inhibition decreases group IIa sPLA2 production in non–small cell lung cancer cells. Tumor
necrosis factor-alpha (TNF-a) for 30 minutes increases production of sPLA2 mRNA (A); *P ¼ .022, n ¼ 3 run in triplicate. A 20-mmol/L dose of
sPLA2 inhibitor decreases sPLA2 mRNA expression (B); *P ¼ .044, n ¼ 3 run in triplicate.
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S20-mmol/L group IIa sPLA2 inhibitor (Figure 3, A and B,
P ¼ .019).
sPLA2 Inhibition Decreases sPLA2 Expression in
A549 Cells
Cells treated with sPLA2 inhibitor show a decrease in
sPLA2 staining by immunofluorescence (Figure 4,
P ¼ .023). Quantitative reverse-transcriptase polymerase
chain reaction shows a significant increase in group IIa
sPLA2 mRNA with TNF-a stimulation for 30 minutes
(Figure 5, A, P ¼ .022) and a decrease in group IIa sPLA2
mRNA in the presence of 20 mmol/L of inhibitor
(Figure 5, B, P ¼ .044).
DISCUSSION
Although previous investigations have linked PLA2 ac-
tivity to ICAM-1 expression, this is the first study to demon-
strate that pharmacologic inhibition of group IIa sPLA2
decreases ICAM-1 expression and invasion in lung cancer
cells.15,18
This effect of sPLA2 inhibition is especially noteworthy
inasmuch as the decrease in ICAM-1 expression is seen in
2 different cell lines that both harbor K-ras mutations but
differ in functional p53 (wild type in A549, mutant in
H358) and liver kinase B1 (mutant in A549 and wild type
in H358) status. Tumor protein 53 is a widely studied tumor
suppressor and liver kinase B1 is an inhibitor of mammalian
target of rapamycin. Unimpeded activity of mammalian tar-
get of rapamycin can be promalignant, and mammalian tar-
get of rapamycin is often aberrantly activated in lung
cancers with oncogenic K-ras mutations.19
The role of adhesion molecules in the pathogenesis, diag-
nosis, and prognosis of cancer has been hotly investigated.
In lung cancer, ICAM-1 and E-cadherin are recognized as
serum markers and, at the cellular level, as role players in
metastatic transformation.2,4 ICAM-1 is inducible by cyto-
kines within the inflammatory milieu of the tumor microen-
vironment. Its potential role in invasion is implicated by
increased in vitro and in vivo invasion with ICAM-1The Journal of Thoracic and Caoverexpression.7 Our experimental approach demonstrates
that by targeting ICAM-1 through a small molecule inhibi-
tor to sPLA2, as well as a neutralizing antibody against cell
surface ICAM-1, invasion was decreased.
Antibody blockade of ICAM-1 resulted in a greater inhi-
bition of invasion than the sPLA2 inhibitor, suggesting
a therapeutic application for an ICAM-1 antibody. Anti-
body therapy targeting adhesion molecules is not ideal be-
cause adhesion proteins are essential for normal leukocyte
function and the risk may outweigh the benefit. Solid tu-
mors are particularly challenging targets for antibody ther-
apy secondary to poor tumor penetration compared with
small molecules.20 Despite decades of research, the Food
and Drug Administration has not yet approved any mono-
clonal antibody available for lung cancer. Importantly,
small molecule inhibitors like the sPLA2 inhibitor can
achieve the same goal of reducing ICAM-1 expression, in
addition to exhibiting other antitumor effects, for less im-
mune reactivity and expense.
PLA2 enzymes produce arachidonic acid, a precursor to
products of cyclooxygenase enzymes such as prostaglan-
dins. Prostaglandins have been implicated in the patho-
genesis of epithelial-derived tumors and prostaglandin
production is elevated in tumor specimens of patients
with lung cancer.21 In vivo studies of cyclooxygenase-2
inhibitors have shown therapeutic trends. A clinical trial
of celecoxib in non–small cell lung cancer is associated
with decreased biomarkers associated with metastatic po-
tential.22 In addition to its enzymatic activity, sPLA2 also
functions as a ligand with the ability to interact with cell
surface receptors like CD40, of the TNF-a receptor fam-
ily, to enhance monocyte response to inflammatory states
and possibly potentiate PLA2 pathways.
11 In this way,
sPLA2 secreted by cancer cells or tumor-associated cells
may act as a ligand to further potentiate inflammatory
cell signals associated with ICAM-1 expression.23 Effec-
tive sPLA2 inhibition may have an added advantage
over cyclooxygenase-2 inhibitors by decreasing this
potentiation.rdiovascular Surgery c Volume 143, Number 2 409
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SA striking result of this study is the finding that cellular
inhibition of group IIa sPLA2 in lung cancer cells decreases
the production of the enzyme itself. Potential mechanisms
could be through decreased transcriptional regulation either
by the enzyme itself or through downstream products. In ad-
dition, lung cancer cell apoptosis increases with prolonged
exposure to sPLA2 inhibition.
17 The combination of
decreased invasion and cancer cell viability from sPLA2
inhibition favors its potential as a therapeutic agent. As
specific group IIa sPLA2 inhibitors have already been stud-
ied in clinical trials for rheumatoid arthritis and sepsis,
their potential application in malignancy is particularly
appealing.24,25
The mechanism of sPLA2 inhibition on ICAM-1 expres-
sion is likely dependent on the transcription factor nuclear
factor-kB.9,10,16 Elucidation of intracellular pathways
affected by group IIa sPLA2 inhibition in lung cancer
cells is the topic of ongoing research.
In summary, these data suggest that sPLA2 plays a signif-
icant role in mediating the inflammatory signals that induce
ICAM-1 expression in lung cancer cells. In addition, this
study demonstrates that pharmacologic inhibition of the en-
zyme can significantly decrease ICAM-1 expression and
subsequent cancer cell invasion. This lays the groundwork
for further investigation into the cellular mechanisms of
sPLA2 and the effect of sPLA2 on lung cancer proliferation
in vitro and in vivo.References
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DrMichael Mulligan (Seattle, Wash). Congratulations on your
paper and a very nice presentation. I always appreciate seeing a lot
of effort put intowork, and clearly you did that. I noticed the article
that your group put out via e-publication last month evaluating
ICAM regulation with sPLA2 in esophageal cancer cells, and
this is a nice extension of that work. It is always difficult to
know what the next great research question is and you seem to
be onto something here.
I have 3 questions, which I will ask one at the time.
The matrigel assay is used to screen cell lines and measure in-
vasiveness, but ultimately it is a dead matrix and is devoid of either
known or candidate ligands for ICAM-1. If you do a quick search,
you can find that there is now a body of researchers who are look-
ing at ICAM-1 not so much as an adhesion receptor, particularly in
the invasion paradigm, but as a signaling molecule. That is a littleery c February 2012
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Sbit different. Indeed, your findings suggest that your greatest
effects on invasiveness were with direct inhibition of ICAM-1
and not with sPLA2 inhibition indirectly, thereby affecting expres-
sion of ICAM-1. Can you postulate how ICAM-1 is regulating
invasiveness? Is it merely adjusting the phenotype or something
more invasive, or how does blockade of ICAM-1 allow you to
digest through a collagen matrix differently than without?
Dr Yu. ICAM-1 can be considered a phenotype of invasive
cells. How it helps the tumor cells invade through the matrix or,
more important, in an in vivo model promote metastatic disease,
is not well defined. There are other mediators of invasion that
we did not necessarily address here, such as metalloproteinases
that help digest the matrix. ICAM-1 is a reasonable marker of in-
vasion given all of the evidence in serum and in tumor tissue. There
are always limitations to in vitro studies, and I think the next move
is to try sPLA2 inhibition in an in vivo model.
Dr Mulligan. It is exciting because with direct blockade you
definitely showed an effect; yet there is no ICAM ligand in the as-
say, so it has to be signaling somehow. There is a lot of potential
there for another award.
The second question relates to specificity and loss of specificity
with S3319, also known as KHO64. If you look at the dose ranges
or the therapeutic concentrations for most of the small molecule
targeted interventions that we use, like Tarceva (Hoffmann-La
Roche, Basel, Switzerland) or any other ‘‘nibs,’’ they are always
in the low nanomolar range, yet you were using up to 40 mmol/L.
What data do you have to assess for loss of specificity or potential
off-target effects?
DrYu. It is difficult to correlate concentrations that are used invi-
tro with an eventual in vivo concentration. One thing we did do was
look at the cytotoxicity of the small molecule inhibitor in the lung
cancer cells using a lactic dehydrogenase cytotoxicity assay. All
the concentrations and time points we used were viable for the cells.The Journal of Thoracic and CaDrMulligan.However, you are seeing something weird, too, in
that you are seeing an enzyme inhibitor having a sort of an auto-
crine reverse effect on transcription of the enzyme itself. It could
be that you have disrupted all sorts of transcriptional mechanisms
that you just have not tracked yet, so it would be good to go back
and look at that.
The last question is a more global one. Activation of sPLA2 is
a fairly upstream activation event, particularly if you try to relate
it to ICAM-1 activation. There are a lot of intervening steps., in-
cluding activation of cyclooxygenase. For the past 20 years there
has been a lot of work looking at inhibition of those intermediate
steps that should theoretically work reasonably well, but they do
not work. I found about 100 publications or more this morning
that demonstrated efficacy in cell systems and more than 50 clin-
ical trials that showed that nothing worked when they tried to take
it forward.What makes this different?Why should this work and is
it safe? Because it is such an omnipresent enzyme that has so many
functions, if we knock it out, what are we going to do to the wild
type or to the patient?
Dr Yu. sPLA2 is upstream. One of the interesting things about
this particular enzyme is that it generates arachidonic acid, but it
also has someother effects. For example, sPLA2 can function as a li-
gand and not just as an intracellular enzyme. These other functions
may be targeted with inhibition of sPLA2. In terms of sPLA2 being
used in humans andwhether or not it is toxic, sPLA2 inhibitors have
been used in trials for rheumatoid arthritis and sepsis. There were
no noticeable toxicities. Finally, regarding the idea that there could
be a single shot approach to addressing anything involving cancer
or invasiveness in particular, sPLA2 inhibition is useful as a research
tool and may eventually be part of multimodality therapy targeting
different pathways that promote malignancy.
Dr Mulligan. Perhaps this is one pathway but maybe not the
pathway.rdiovascular Surgery c Volume 143, Number 2 411
